Full-Time

Engineer – Automation Applications/Surgical Robotics

Ottava

Posted on 5/9/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$91k - $129.5k/yr

+ Long-term incentive program

Santa Clara, CA, USA

In Person

Category
Mechanical Engineering (2)
,
Required Skills
Python
C#
Requirements
  • Bachelor’s degree in Mechanical Engineering, Electrical Engineering, Mechatronics Engineering, Robotics Engineering, Computer Engineering, or Manufacturing Engineering
  • Less than 3 years of experience in industrial automation/robotics
  • Hands-on interest in automation including industrial robotics; willingness to learn robot cell layout, EOAT fundamentals, machine safety basics, and cycle-time optimization
  • Basic scripting or programming for automation or data tasks (e.g., Python, C#, or PLC Structured Text)
  • Strong engineering fundamentals including root-cause analysis across mechanical, electrical, controls, and software interfaces; basic debugging; and mechanical design fundamentals
  • Familiarity with industrial networking/operational technology concepts (e.g., EtherNet/IP, PROFINET, OPC UA, MQTT) and willingness to learn basic network troubleshooting
  • Safety-first mindset and willingness to learn safe design practices (risk assessments, guarding, interlocks)
  • Interest in Lean/Continuous Improvement and using data to improve overall equipment effectiveness, throughput, quality, and yield
  • May require up to 5% domestic and/or international travel
Responsibilities
  • Drive automation solutions from design through commissioning and handover (factory acceptance testing and site acceptance testing, installation qualification and operation qualification where applicable, run-at-rate)
  • Support senior engineers in implementing semi-automated to fully automated solutions, including X-Y Cartesian systems, robotic cells, end-of-arm tooling, vision-guided assembly, smart workstations, and autonomous mobile robots
  • Support development of functional specifications (user requirements specification and functional requirements specification), test plans, acceptance criteria, and commissioning/validation documentation
  • Participate in system design reviews and help provide technical direction to internal teams and integrators to ensure modular, scalable, and maintainable designs
  • Specify, integrate, and validate automation hardware and software (robots, programmable logic controllers, human-machine interfaces, safety controllers, vision systems, sensors, actuators, and industrial networks)
  • Support machine safety and risk assessments (guarding, interlocks, collaborative robot safety) and maintain environment, health and safety compliance documentation
  • Follow functional safety and standards compliance for robot cells and AMR operations (e.g., International Organization for Standardization 10218/Technical Specification 15066, ISO 13849/IEC 62061, ISO 12100)
  • Implement operational technology/internet of things connectivity, edge devices, and monitoring (equipment status, alarms, cycle time, overall equipment effectiveness drivers); collaborate on dashboards and analytics
  • Support and maintain automation standards, reusable libraries, and digital engineering artifacts (robot simulation, offline programming, digital twin where applicable)
  • Partner with manufacturing, operations, quality, information technology, and cybersecurity to deliver automation solutions
  • Work with suppliers and system integrators, including request for quotation and statement of work development, technical delivery support, schedule tracking, and basic budget management for automation projects
Desired Qualifications
  • Internship/co-op or project experience in manufacturing/automation (robotics, controls, test, equipment engineering, or process engineering)
  • Exposure to programmable logic controllers controls (e.g., Rockwell/Allen-Bradley, Beckhoff, Siemens) through coursework, labs, internships, or projects; ability to troubleshoot input/output, motion, and basic safety concepts is a plus
  • Exposure to robotics, vision, or motion systems (e.g., ABB, KUKA, Universal Robots; Cognex/Keyence; servo systems) through labs, internships, or personal projects
  • Basic data/quality tools (e.g., statistical process control concepts, capability analysis, Pareto, 5-Why) and comfort working with production data in Excel or similar tools
  • Familiarity with regulated product environments (medical device/pharmaceutical), including documentation rigor, change control, and validation concepts (IQ/OQ/PQ)
  • Exposure to Industry 4.0 / IIoT integration (e.g., OPC UA, MQTT, REST APIs) and/or basic SQL, log review, and troubleshooting of data pipelines
  • Experience collaborating with vendors/system integrators (e.g., contributing to RFQs/SOWs, reviewing designs, supporting FAT/SAT action items)

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.